BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 37344881)

  • 21. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
    Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
    Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Li-Fraumeni syndrome].
    Sejben A; Tiszlavicz L; Polyák K; Kovács L; Maráz A; Török D; Leprán Á; Ottlakán A; Furák J
    Orv Hetil; 2019 Feb; 160(6):228-234. PubMed ID: 30730202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelioid angiomyolipoma of the liver in a patient with Li-Fraumeni syndrome: a case report.
    Yang Y; Lee J; Woo CG; Lee OJ; Son SM
    Diagn Pathol; 2024 Jan; 19(1):16. PubMed ID: 38243242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
    Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
    Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
    Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
    Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.
    Chao A; Lai CH; Lee YS; Ueng SH; Lin CY; Wang TH
    BMC Cancer; 2015 Jan; 15():8. PubMed ID: 25588929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
    Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor.
    Prejac J; Dedić Plavetić N; Gotovac Jerčić K; Borovečki F
    World J Surg Oncol; 2021 Aug; 19(1):254. PubMed ID: 34452612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome.
    Talwalkar SS; Yin CC; Naeem RC; Hicks MJ; Strong LC; Abruzzo LV
    Arch Pathol Lab Med; 2010 Jul; 134(7):1010-5. PubMed ID: 20586629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
    Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
    Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.
    Etzold A; Schröder JC; Bartsch O; Zechner U; Galetzka D
    Fam Cancer; 2015 Mar; 14(1):161-5. PubMed ID: 25226867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
    Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
    Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
    Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
    Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmission of a
    Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.